| Market Capitalization (Millions $) |
799 |
| Shares
Outstanding (Millions) |
251 |
| Employees |
294 |
| Revenues (TTM) (Millions $) |
418 |
| Net Income (TTM) (Millions $) |
-7 |
| Cash Flow (TTM) (Millions $) |
42 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Esperion Therapeutics Inc. is a biopharmaceutical company based in the United States that specializes in developing and commercializing innovative therapies for the treatment of cardiovascular diseases. The company's primary focus is on developing oral, targeted therapies designed to lower elevated levels of low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia, a condition associated with an increased risk of cardiovascular disease. Esperion Therapeutics' lead product candidate is bempedoic acid, which has shown promising results in lowering LDL-C levels and improving cardiovascular outcomes in clinical trials. The company is committed to addressing the unmet medical needs of patients and aims to provide safe and effective therapeutic options for the prevention and treatment of cardiovascular diseases.
Company Address: 3891 Ranchero Drive, Suite 150 Ann Arbor 48108 MI
Company Phone Number: 887-3903 Stock Exchange / Ticker: NASDAQ ESPR
|
0.38% 
54.17 %